Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page; no study content or user-facing details appear to have changed.SummaryDifference0.1%

- Check21 days agoChange DetectedMinor version update from v3.2.0 to v3.3.1. No changes to the study content or trial details are observed.SummaryDifference0.1%

- Check29 days agoChange DetectedThe government operating status banner at the top was removed. The study details, eligibility criteria, locations, and outcomes on the page remain unchanged.SummaryDifference0.4%

- Check43 days agoChange DetectedNo significant changes to core trial information were detected; only minor formatting adjustments were observed, To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check72 days agoChange DetectedUpdated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.SummaryDifference3%

- Check79 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No other substantive content changes are indicated.SummaryDifference0.1%

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.